<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103191</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-KLS-2016-39</org_study_id>
    <nct_id>NCT03103191</nct_id>
  </id_info>
  <brief_title>Diagnostic Value of KL-6 in ILD</brief_title>
  <official_title>Diagnostic Value of KL-6 in Interstitial Lung Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is
      limited information in non-Asian populations. Therefore, it is necessary to carry out studies
      in other populations to confirm the diagnostic values of the biomarker and its prognostic
      implication.

      Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases.
      But it is necessary to know more about its utility in the European population.

      Study Objectives:

        -  To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at
           the time of diagnosis compared to patients without pulmonary fibrosis

        -  Diagnostic yield of KL-6 in patients with pulmonary fibrosis.

        -  Correlation of KL-6 values with functional and radiological parameters of disease
           severity at diagnosis.

        -  Correlation of serum KL-6 values with the evolution of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Serum KL-6 levels in patients with pulmonary fibrosis at the time of diagnosis.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>50 subjects with fibrosing interstitial lung disease.
50 subjects with pulmonary fibrosis secondary to collagen diseases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.
75 subjects with collagen disease without pulmonary fibrosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>KL-6 levels</intervention_name>
    <description>Measure of KL-6 in serum</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects over 18 years of age attending the outpatient clinic at Hospital de la Santa Creu
        i Sant Pau.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects older than 18 years.

          2. Chronic respiratory diseases )including Fibrotic interstitial lung disease, asthma or
             COPD) related or not to a connective tissue disease.

          3. Acceptance of the patient to participate in the study by signing the informed consent
             after having discussed with the researchers the objectives, risks and potential
             benefits.

        Exclusion Criteria:

          1. Absence of informed consent

          2. Psychiatric disorder or limitation of collaboration (including language,
             socio-cultural problem, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Erika Delgado Espinoza</last_name>
      <email>CDelgadoE@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Diego Castillo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

